EMBO/SourceData huggingface dataset:
Figure legend: "(H) Larval brains of control (ctrl; yw), ebd1-Flag overexpression under insc­-Gal4, pr-set7716/Df(3R)ED5644 (716/Df) and pr-set7716/Df with ebd1 induced with insc-Gal4 at 24h ALH were labelled with Dpn and EdU. (I) Quantifications of NSCs without EdU incorporation for larval brains in (H). Control: n=1162, 13 BL; insc&gt;ebd1: n=997, 11 BL; pr-set7716/Df: n=928, 13 BL and pr-set7716/Df with ebd1 induced with insc-Gal4: n=1284, 16 BL. Data information: Data are presented in I) as mean ± SD. n numbers in I) were total NSCs counted with total brain lobes measured, while each brain lobe was considered as one biological replicate. Statistical analyses were done comparing among different genotypes using ordinary one-way ANOVA I). ns: non-significant; *P &lt; 0.05; ***P &lt; 0.001."
NCBI gene IDs:
"ebd1: 38082
Gal4: 855828
pr-set7: 41743"
Figure legend: "(A) Larval NSCs of control (ctrl; yw) and cdk1B47 at 24h ALH were labelled for Earthbound1 (Ebd1), Deadpan (Dpn), and Miranda (Mira). (B) Quantifications of the corrected total cell fluorescence (CCF) of Ebd1 in genotypes in (A). CCF = Integrated Density - (Area of selected cell × Mean fluorescence of background readings). CCFs were 846.9±394.2 for control (ctrl; yw; n=167, 14 BL) and 354.3±245.3 for cdk1B47 (n=211, 13 BL). (C, D) Larval NSCs of control (UAS-dicer2) and UAS-cdk1-Myc induced with insc-Gal4 at 6h ALH were labelled for Ebd1, Dpn, and Mira. (D) Quantifications of the CCF of Ebd1 in genotypes in (C). CCFs were 111.3±80.2 for control (n=157, 12 BL) and 346.6±221.1 for cdk1-Myc (n=181, 12 BL). Data information: Data are presented in (B, D, as mean ± SD. n numbers in (B, D, were total NSCs counted with total brain lobes measured, while each NSC was considered as one biological replicate. White arrows point to NSCs (A, C, Yellow dotted boxes indicate the region of zoomed-in images (A, C, Statistical analyses were done comparing between two different genotypes using Mann-Whitney test (B, D) Scale bars, 15 μm (A, C,"
NCBI gene IDs:
"cdk1: 34411
Gal4: 855828"
Figure legend: "(E) qPCR analysis of cdk1 in larval brains of control (ctrl; yw) and ebd1240 at 24h ALH. n=3 as biological replicates. Statistical analyses were done comparing control (GAPDH1, GAPDH2, Tbp1 and Rpl32) and ebd1240, using two-tailed Student's t-test. The mRNA levels of control were normalized to 1. Data information: Statistical analyses were done comparing between two different genotypes using two-tailed Student's t-test (E)."
NCBI gene IDs:
"GAPDH1: 
GAPDH2: 
Rpl32: 
Tbp1: 
cdk1: 34411
ebd1: 38082"
Figure legend: "Larval NSCs of control (ctrl; yw), ebd1240 and pr-set7716/Df(3R)ED5644 (716/Df) at 24h ALH were stained for Senseless (Sens), Dpn and Mira. (F) Data information: White arrows point to NSCs F). Yellow dotted boxes indicate the region of zoomed-in images F). Scale bars, 15 μm F)."
NCBI gene IDs:
"ebd1: 38082
pr-set7: 41743"
Figure legend: "(A) Real-time quantitative PCR of the indicated genes (M1-like and M2-like macrophages markers) of A375 xenograft treated with PLX4720, bevacizumab or COMBO. Data are presented as expression fold change (log2) compared with vehicle after normalization for housekeeping gene TBP (n=3 tumors), (*P &lt; 0.05, **P &lt; 0.01, ***P &lt; 0.001 versus vehicle (PLX4720: m-Arg1 P = 5.65E-06) (bevacizumab: m-Ccl5 P = 0.025) (COMBO: m-Ccl5 P = 0.0070; m-Cd40 P = 0.00099; m-Cxcl10 P = 0.043; m-Cxcl9 P = 0.046; m-Il1b P = 0.0367; m-Stat1 P = 0.049; m-Tlr2 = 0.00182; m-Arg-1 P = 0.0013)."
NCBI gene IDs:
"TBP: 
Arg-1: 11846
Ccl5: 20304
Cd40: 21939
Cxcl10: 15945
Cxcl9: 17329
Il1b: 16176
Stat1: 20846
Tlr2: 24088"
Figure legend: "(E) Quantitative Real-time PCR of h-TGFB1 and m-Tgfb1 of A375 xenograft treated with PLX4720, bevacizumab or COMBO. Data are presented as expression fold change (log2) compared with vehicle after normalization for the housekeeping gene TBP (n=3 tumors), *P &lt; 0.05 versus vehicle (P = 0.043)."
NCBI gene IDs:
"TBP: 
TGFB1: 7040
Tgfb1: 21803"
Figure legend: "(G) Real-time quantitative PCR of h-TGFB1 of A375 xenograft treated with PLX4720, bevacizumab or COMBO. Data are presented as expression fold change (log2) of relapsing tumors compared to responder tumors after normalization for housekeeping gene TBP (n=3 tumors) ***P &lt; 0.001 versus vehicle (P = 0.0006)."
NCBI gene IDs:
"TBP: 
TGFB1: 7040"
Figure legend: "I,J.  Luciferase activity controlled by the upstream 5'UTR fragment from Sox2  (WT and mutant), Rps21  (WT and mutant) and Actb. Treatments were applied for 12h. Data is normalized to vehicle and is represented as mean ± SD. n = 6 biological replicates. Two-way ANOVA with Tukey's multiple comparisons test (p-value specified). Data information: p ≡ p-value."
NCBI gene IDs:
"Rps21: 66481
Sox2: 20674"
Figure legend: "B. vSVZ  niche FACS  quantifications of total NSCs  (Total NSCs) &amp; immunofluorescence  quantification of aNSCs   (Fraction of aNSCs) in WT or IFNAGR  KO mice  at 2, 7 and 22 months old (MO). Data from individual mice  is plotted. Inferred dynamics are depicted as a blue (WT) or red (IFNAGR  KO) line over time. Sample sizes: WT total at 60 days: 8 mice, WT total at 210 days: 3 mice, WT total at 660 days: 3 mice, WT fraction aNSCs   at 60 days: 3 mice, WT fraction aNSCs    at 660 days: 4 mice, IFNAGRKO total at 60 days: 8 mice, IFNAGRKO total at 180 days: 3 mice,  IFNAGRKO total at 660 days: 3 mice,  IFNAGRKO fraction aNSCs   at 60 days: 3 mice, IFNAGRKO fraction aNSCs   at 660 days: 3 mice."
NCBI gene IDs:
"IFNAGR: 15975///15979"
Figure legend: "Cells were infected with HIV-1 R5 Vpr-Blam for 4h or 48h and then incubated with CCF2 for 5 h at 11°C to prevent particle fusion during the staining process. For the indicated sample, T20 was added at the moment of infection. (E) Percentage of positive cells for the presence of the CFF2 product at 4h p.i. ** p&lt;0.01calculated with 2way ANOVA test."
NCBI gene IDs:
"Blam: 
Vpr: 155807"
Figure legend: "Cells were infected with HIV-1 R5 Vpr-Blam for 4h or 48h and then incubated with CCF2 for 5 h at 11°C to prevent particle fusion during the staining process. For the indicated sample, T20 was added at the moment of infection. (F-G) Percentage of positive cells for the presence of the CFF2 product at 4h p.i. (left) and 48h p.i. (right) *p&lt;0.05 calculated with 2way ANOVA test. The graphs show mean values +/- SD for cells from five and three donors, respectively."
NCBI gene IDs:
"Blam: 
Vpr: 155807"
Figure legend: "iDCs were spin-transduced with VLPs carrying Vpxmac239 one day prior to infection. Cells were incubated with anti-DC-SIGN and anti-MMR blocking antibody or isotype control for 30 min, infected with HIV-1 R5 Vpr-Blam for 4 hours to asses fusion or for 48 hours to asses productive infection. (I) Percentage of positive cells for the presence of the CFF2 product at 4 hours p.i. (J) Percentage of p24+ cells at 48 hours p.i. The graphs show mean values +/- SD for cells from three donors. *p&lt;0.05 calculated with 2way ANOVA test."
NCBI gene IDs:
"Blam: 
Vpr: 155807
Vpx: 1490006"
Figure legend: "(H) iDC differentiated from peripheral blood monocytes for five days were spin-transduced with VLPs carrying Vpxmac239. One day later, iDCs were infected with HIV-1 R5 and cultured in 2D suspension, 2D collagen or 3D collagen. Productive infection was analyzed by p24 intracellular staining and FACS at 4 (d.p.i). The graph depicts mean values for cells from two donors."
NCBI gene IDs:
"Vpx: 1490006"
Figure legend: "(A) miR-515-5p expression increases the area of the tubulin cytoskeleton. Tubulin (green) and cell nucleus (blue). Objective x20. Bar: 200 µm."
NCBI gene IDs:
"miR-515-5p: 574465///574462"
Figure legend: "(B-C) miR-515-5p inhibits random (B) and directed (C) cell migration. The indicated cell lines were transfected with miR-515-5p for 48 h before time-lapse imaging was performed for 18 h (A) or transwell migration assays were performed for 9 h (C). (B-left panel) Plots show overlays of representative trajectories travelled. (B-right panel) The distance of migration was quantified and represented as the mean ± SEM of values normalised to the respective control condition. (C-left panel) Representative field of view from the bottom of the transwell chambers. Scale bar is 20 µm. (C-right panel) Data represent percentage of the average number migratory cells per field (n=5 fields per condition). Data are mean of three experiments ± SEM. (B-C) P values were calculated by t-test between miRNA (515-5p) values and their respective non-targeting control miR (NC) values (***, P&lt;0.001). All data shown are representative of experiments performed at least in triplicate."
NCBI gene IDs:
"miR-515-5p: 574465///574462"
Figure legend: "(A) RNA-seq of MCF7 and MDA-MB-231 transfected with miR-515-5p revealed the down-regulation of five transcripts, NRAS, FZD4, CDC42BPA, PIK3C2B and MARK4."
NCBI gene IDs:
"CDC42BPA: 8476
FZD4: 8322
MARK4: 57787
miR-515-5p: 574462///574465
NRAS: 4893
PIK3C2B: 5287"
Figure legend: "(B-D) The effect of miR-515-5p overexpression on NRAS, FZD4, CDC42BPA, PIK3C2B and MARK4 mRNA levels in MCF7 (B), MDA-MB-231(C), A549 and H1299 (D) was determined by qPCR 48 h following transfection of the indicated cell line with non-targeting control miR (NC) or miR-515-5p. Data is displayed as the normalised mean ± SEM. P values were calculated by t-test between miRNA conditions and their respective NC conditions (*, P&lt;0.05; **, P&lt;0.01; ***, P&lt;0.001)."
NCBI gene IDs:
"CDC42BPA: 8476
FZD4: 8322
MARK4: 57787
miR-515-5p: 574462///574465
NRAS: 4893
PIK3C2B: 5287"
Figure legend: "(E-F) miR-515-5p directly interacts with NRAS, MARK4 and PI3KC2B's 3'UTR. Relative luciferase activity levels were measured 24 h after co-transfection of MCF-7 (E) and MDA-MB-231 (F) with 3'UTR-luciferase reporter constructs and either with miR-515-5p or miR NC. Data shown are normalised mean of three independent experiments ± SEM. (B-F) P values were calculated by t-test between miRNA conditions and their respective NC conditions (*, P&lt;0.05; **, P&lt;0.01; ***, P&lt;0.001)."
NCBI gene IDs:
"luciferase: 
MARK4: 57787
miR-515-5p: 574465///574462
NRAS: 4893
PI3KC2B: 5287"
Figure legend: "MARK4 siRNA-mediated silencing increases the tubulin cytoskeletal area (A). (A) Data shown are representative of experiments performed in triplicate. Bar graph represents the average ± SEM of n ≥ 50 per technical replicate with 3 technical replicates per conditions."
NCBI gene IDs:
"MARK4: 57787"
Figure legend: "MARK4 siRNA-mediated silencing reduces random (B) migration in MDA-MB-231 (MDA), A549 and H1299 cells.Cells were transfected either with siRNA targeting MARK4 (M4) or a non-targeting control (NC) for 48 h before time-lapse imaging was performed for 18 h (B). (B-top panel) Plots show overlays of representative trajectories described. (B-bottom panel) The migration distance was quantified and represented as the normalised mean ± SEM. (C-top panel) Representative field of view from the bottom side of the transwell membrane. (C-bottom panel) Graphs indicate cell migration expressed as a percentage of the average of migratory cells per field (n=5 fields per condition). (B-C) Data are mean of three experiments ± SEM. (A-C) P values were calculated by t-test between the siRNA-transfected and the respective control condition (***P&lt;0.001)."
NCBI gene IDs:
"MARK4: 57787"
Figure legend: "MARK4 siRNA-mediated silencing reduces directed (C) migration in MDA-MB-231 (MDA), A549 and H1299 cells.(C-top panel). Cells were transfected either with siRNA targeting MARK4 (M4) or a non-targeting control (NC) for 48 h before transwell assay for 9h (C). Representative field of view from the bottom side of the transwell membrane. (C-bottom panel) Graphs indicate cell migration expressed as a percentage of the average of migratory cells per field (n=5 fields per condition). (B-C) Data are mean of three experiments ± SEM. (A-C) P values were calculated by t-test between the siRNA-transfected and the respective control condition (***P&lt;0.001)."
NCBI gene IDs:
"MARK4: 57787"
Figure legend: "(A-B) The indicated cell lines were transfected with either miR-515-5p or a non-targeting miR (miR NC) together with a MARK4 expressing or an empty vector (EV) plasmid DNA. MARK4 over-expression rescues the inhibition by miR-515-5p of random (A) and directed (B) migration of the indicated cell lines. (A-left panel) Plots show overlays of representative trajectories described for MDA-MB-231 cells (n=30). (A-right panel) The migration distance was quantified and represented as the normalised mean ± SEM. (B-left panel) Representative field of view from the bottom side of the transwell membrane for MDA-MB-231. (B-right panel) Graphs indicate cell migration expressed as a percentage of the average of migratory cells per field (n=5 fields per condition). Data are mean of three experiments ± SEM. (A-C) P values were calculated by t-test between the transfected and the respective control condition (EV+miR-NC) (*,P&lt;0.05; **,P&lt;0.01; ***,P&lt;0.001)."
NCBI gene IDs:
"MARK4: 57787
miR-515-5p: 574462///574465
miR-515-5p: 574465///574462"
Figure legend: "(A-B) Overall survival of ER-negative metastatic breast cancer (n=226) (A) and lung adenocarcinoma (n=719) (B) patients according to MARK4 mRNA levels found in their tumors was represented using the Kaplan Meier-plotter [25]."
NCBI gene IDs:
"MARK4: 57787"
Figure legend: "(C) A cDNA array for 24 matched lung cancers and surrounding normal tissue was analysed for MARK4 expression. Expression levels from tumors were normalised to their respective normal control and the percentage of cases for the indicated fold expression in the tumor represented as a pie-chart."
NCBI gene IDs:
"MARK4: 57787"
Figure legend: "(D-F) MARK4 protein expression was determined by histoimmunochemistry in (D-E) a tissue microarray comprising 90 lung tumor and 10 normal lung samples or (F) a home-made tissue microarray comprising 100 matched cases of primary and metastatic tumors. (D-E) The percentage of positivity for MARK4 staining in lung tumors versus normal lung samples (D) or in lung tumors according to their histological subtypes (E) is represented. (F) The percentage of cases with increased, decreased or unchanged levels of MARK4 in metastatic lesions as compared to the corresponding primary tumors is represented."
NCBI gene IDs:
"MARK4: 57787"
Figure legend: "(A-D) Low expression of miR-515-5p is linked to survival in both Lung and Breast cancer. (A) Survival analysis of miR-515-5p from 195 lung adenocarcinoma samples from the TCGA. (B) Survival analysis of miR-515-p from 34 lung squamous cell carcinoma from the TCGA. (C) Survival analysis of miR-515-5p from 60 Breast cancer samples from the Lyng Ditzel Breast Study (GSE37405). (D) Survival analysis of miR-515-5p from 33 Breast cancer from the GSE7405 Breast study. Analysis and plot were obtained with SurvMicro http://bioinformatica.mty.itesm.mx:8080/Biomatec/Survmicro.jsp for (A-C) and with MIRUMIR for (D)."
NCBI gene IDs:
"miR-515-5p: 574465///574462
miR-515-p: 574465///574462"
Figure legend: "(E) Comparison of miR-515-5p expression in 18 primary and matched metastatic lesions from breast cancer patients. miR-515-5p levels were quantified by TaqMan qRT-PCR. Absolute values were normalized to u6 snRNA values and displayed as a dot-plot. Bar; Mean, Whiskers; SEM."
NCBI gene IDs:
"u6: 
miR-515-5p: 574465///574462"
Figure legend: "(F) MDA-MB-231 cells were inoculated into the mammary fat pads of nude mice and allowed to form metastatic deposits [22]. miR-515-5p and MARK4 levels were then determined in the primary and indicated secondary lesions. Data are average ± SEM of technical triplicates."
NCBI gene IDs:
"MARK4: 57787
miR-515-5p: 574465///574462"
Figure legend: "(G) Luciferase-expressing A549 cells overexpressing miR-515-5p or a non-targeting control (miR-NC) were injected in the tail-vein of SCID mice and the development of tumor burden monitored by whole animal-imaging in response to luciferin administration at week 1 and 4 following injection. (G-left panel) Representative imaging of the same animals for the indicated conditions at week 1 and 4. (G-Right panel) The emitted photons were quantified and the signals normalised to the corresponding readings at week 1. Data represented are representative of three independent experiments. (E-G) P values were calculated by t-test (*, P&lt;0.05; **, P&lt;0.01; ***, P&lt;0.001)."
NCBI gene IDs:
"Luciferase: 
miR-515-5p: 574465///574462"
Figure legend: "A549-Luc cells transfected either with miR-515-5p precursor (miR), siRNAs to MARK4 (siMARK4) or the corresponding control sequences (C and NT, respectively) were injected in Scid mice through the tail vein. 4 weeks later, the mice were sacrificed, their lungs extracted and fixed prior to staining for Luciferase expression. (A) Representative pictures showing the presence of A549-Luc cells in the lungs of NT mice either as single cells (upper panel) or as a tumour mass (lower panel). (B) Percentage of the area covered by tumour cells on randomly observed fields of views. Quantification was performed using Photoshop CS4. Each spot corresponds to quantification of an individual 1 mm x 1.5 mm field. Transversal bar; Median. Statistics: Student t-test. *, p≤0.05."
NCBI gene IDs:
"Luc: 
Luciferase: 
MARK4: 57787
miR-515-5p: 574465///574462"
Figure legend: "Single-cell RNA sequencing was performed to profile cell populations in normal mouse pancreas (n = 2), early KIC (40-day-old, n = 2) and late KIC (60-day-old, n = 3) pancreata. Samples from the same stage were pooled. Violin plots of expression of Il6, Tgfbr1 and Tgfbr2 in distinct cell populations is shown."
NCBI gene IDs:
"Il6: 16193
Tgfbr1: 21812
Tgfbr2: 21813"
Figure legend: "Pearson and Spearman correlation of the expression of IL6 and TGFBR2 in PDA patients from TCGA (n = 223) using R."
NCBI gene IDs:
"IL6: 3569
TGFBR2: 7048"
Figure legend: "CAF-PC2 cells were treated with TGFβ (30 ng/ml) for 24 hours with siRNA-mediated knockdown of JUNB, JUND, SMAD4 or RELA. CM was collected and subjected to human IL-6 ELISA."
NCBI gene IDs:
"JUNB: 3726
JUND: 3727
RELA: 5970
SMAD4: 4089"
Figure legend: "CAF-PC2 cells were treated with IL-1α (1 ng/ml) (H) for 24 hours with siRNA-mediated knockdown of JUNB, JUND, SMAD4 or RELA. M was collected and subjected to human IL-6 ELISA."
NCBI gene IDs:
"JUNB: 3726
JUND: 3727
RELA: 5970
SMAD4: 4089"
Figure legend: "Overall survival of PDA patients from TCGA with and without TGFBR2 mutation."
NCBI gene IDs:
"TGFBR2: 7048"
Figure legend: "Loss-of-function mutation of Tgfbr2 was generated by CRISPR with two different gRNAs (mut1 and mut2) in the mouse PDA cell line BMFA3 derived from KPfC model. Control cell line (Tgfbr2wt) and two Tgfbr2-mutant cell lines (Tgfbr2mut1 and Tgfbr2mut2) were treated with TGFβ (30 ng/ml) for 5 hours. Cell lysates were harvested and western blotting for P-SMAD2, SMAD2, SMAD4, P-ERK1/2, ERK1/2, P-P38, P38, and actin was performed."
NCBI gene IDs:
"Tgfbr2: 21813"
Figure legend: "Immunofluorescence was performed to study the expression and localization of E-cadherin and SMAD4 after TGFβ treatment (30 ng/ml for 24 hours) in control cell line and two Tgfbr2-mutant cell lines. Scale bars = 50 μm (fluorescent), scale bars = 100 μm (brightfield)."
NCBI gene IDs:
"Tgfbr2: 21813"
Figure legend: "Control cell line (Tgfbr2wt) (A) and two Tgfbr2-mutant cell lines (Tgfbr2mut1 and Tgfbr2mut2) (B-C) were treated with TGFβ at different time points, and cell growth (MTT) assays were performed. P value by t test is shown. NS, not significant."
NCBI gene IDs:
"Tgfbr2: 21813"
Figure legend: "Subcutaneous tumors established from control cell line (D) and two Tgfbr2-mutant cell lines (E-F) in C57Bl/6 mice received rat IgG Mac48 (control) or 2G8 (each 30 mg/kg 2x/week, n = 4/group). Therapy started at day 12 post tumor cell injection; mice were on therapy for 16 days. Tumor volume was measured twice per week. P values by t test are shown."
NCBI gene IDs:
"Tgfbr2: 21813"
Figure legend: "Control cell line (Tgfbr2wt; G&amp;I) and the Tgfbr2-mutant cell line (Tgfbr2mut1; H&amp;J) were orthotopically implanted in C57Bl/6 mice. Mice received rat IgG Mac48 or 2G8, n = 9-10/group for survival study (each 30 mg/kg 2x/week)."
NCBI gene IDs:
"Tgfbr2: 21813"
Figure legend: "Control cell line (Tgfbr2wt; G&amp;I) and the Tgfbr2-mutant cell line (Tgfbr2mut1; H&amp;J) were orthotopically implanted in C57Bl/6 mice. Mice were sacrificed when they became moribund. Tumors were harvested and weighed (K-L)."
NCBI gene IDs:
"Tgfbr2: 21813"
Figure legend: "Control shRNA or two different shRNAs against IL6RA were used to knock down IL6RA in the Tgfbr2-mutant cell line Tgfbr2mut1. Cell lysates were harvested and western blotting for IL6RA and tubulin."
NCBI gene IDs:
"IL6RA: 16194
Tgfbr2: 21813"
Figure legend: "3D culture: control or IL6RA knockdown Tgfbr2mut1 cells were seeded on poly-HEMA-coated 96-well plates and cultured for 4 days (5000 cancer cells for monoculture, 3000 cancer cells + 2000 NIH 3T3 for co-culture)."
NCBI gene IDs:
"IL6RA: 16194
Tgfbr2: 21813"
Figure legend: "3D culture: control or IL6RA knockdown Tgfbr2mut1 cells were seeded on poly-HEMA-coated 96-well plates and cultured for 4 days (5000 cancer cells for monoculture, 3000 cancer cells + 2000 NIH 3T3 for co-culture). Control IgG, 2G8 and IL-6 neutralizing antibody (each 100 ng/ml, n = 5/group). Scale bars = 50 μm. P values by t test are shown (C)."
NCBI gene IDs:
"IL6RA: 16194
Tgfbr2: 21813"
Figure legend: "Subcutaneous tumors established from control and IL6RA knockdown Tgfbr2-mutant cell lines in C57Bl/6 mice received rat IgG Mac48 (control), 2G8 or anti-mouse IL-6 antibody MP5-20F3 (each 30 mg/kg 2x/week, n = 5/group). For NK cell depletion, prior to therapies, mice received 50 μg of control rabbit IgG or anti-Asialo-GM1 three days in a row. For maintenance, 25 μg of control rabbit IgG or anti-Asialo-GM1 were given 2X/week throughout the whole study. Therapy started at day 12 post tumor cell injection and mice were on therapy for 16 days. Tumor volume was measured twice per week. P values by t test are indicated."
NCBI gene IDs:
"IL6RA: 16194
Tgfbr2: 21813"
Figure legend: "(A) NSCLC expressing single site mutants of EGFR, PC9 (3X106) or H3255 (8X106), were seeded in 10-cm dishes. On the next day, complete media were replaced with media containing serum (1%) and the cells were treated for 24 hours with different EGFR-specific TKIs (erlotinib, 50 nM; osimertinib, 50 nM, or afatinib, 10 nM), either alone or in combination with 2XmAbs (cetuximab and trastuzumab, 5 μg/ml each). Thereafter, cells were washed with cold saline and extracted. Proteins were separated using gel electrophoresis and transferred onto nitrocellulose membranes. After blocking, membranes were incubated overnight with the indicated primary antibodies, followed by incubation with horseradish peroxidase-conjugated secondary antibodies (60 minutes), and treatment with Clarity™ Western ECL Blotting Substrates (Bio-Rad). ECL signals were detected using the ChemiDoc™ Imaging System (Bio-Rad) and images were acquired using the ImageLab software. Signals (relative to Control) were quantified and normalized to the signals of GAPDH (numbers shown below each lane)."
NCBI gene IDs:
"EGFR: 1956"
Figure legend: "PC9 cells (3X106/mouse) were subcutaneously implanted in the flanks of CD1-nu/nu mice. When tumors became palpable, mice were randomized in groups of 5-9 animals and treated for 90 days (grey areas) with 2XmAbs (cetuximab plus trastuzumab, 0.2 mg/mouse/injection), once every three days, or with erlotinib (50 mg/kg/day), once per day. Alternatively, mice were treated with combinations of erlotinib (50, 20, 10, 5 or 1 mg/kg) and the two monoclonal antibodies. Following 60 days of treatment reduced the frequency of erlotinib administration to once every other day (underneath dotted line). animal survival (B) are shown. Mice were euthanized when tumor size reached 1,500 mm3."
NCBI gene IDs:
"CD1: 111334"